-
Posted by
Two Blokes Jul 10 -
Filed in
Stock
-
4 views
Klotho Neurosciences (NASDAQ:KLTOW) announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan Drug Designation from the US Food and Drug Administration (FDA), The news sent Klotho's shares higher in early trade on Thursday, up 5.8% at about $1.45. ALS is a rare, progressive neurodegenerative disease commonly known as Lou Gehrig's disease.
